The deletion of two cancer genes, CHD1 and MAP3K7, improves how well tumors respond to cancer immunotherapy and could be used ...

Using CRISPR co-culture screens, researchers found that deleting CHD1 and MAP3K7 makes tumor cells more vulnerable to immune ...

Universal gene‑edited CAR‑T therapies turn donor T cells into off‑the‑shelf cancer treatments, cutting delays and costs while ...

A new publication from CorriXR Therapeutics, an oncology focused biotherapeutics company developing genetic medicines to overcome drug resistance in solid tumors, shows that its novel CRISPR-directed ...

For the first time, scientists have found a way to efficiently and precisely remove genes from white blood cells of the immune system and to insert beneficial replacements, all in far less time than ...

Study in Molecular Therapy Oncology shows gene editing restores drug sensitivity by targeting NRF2, with potential across multiple tumor types In a major step forward for cancer care, researchers at ...

Two studies published in Nature Medicine June 11 contribute to a small body of literature suggesting cells edited with CRISPR-Cas9 may cause cancer. Here are five things to know about the studies and ...

A glucose-sensitive nanovaccine delivers CRISPR to tumors, silences immune-suppressing genes, and activates a targeted immune response against cancer. (Nanowerk Spotlight) Immune-based cancer ...

Much of pancreatic cancer’s evasive and deadly nature may come down to low levels of one gene. In A Nutshell Early detection, ...

Gene editing is rewriting the future of medicine, as seen in the case of a baby named KJ Muldoon who got a fully personalised ...

In a major step forward for cancer care, researchers at ChristianaCare’s Gene Editing Institute have shown that disabling the NRF2 gene with CRISPR technology can reverse chemotherapy resistance in ...